Autotransfusion Market Size, Share & Trends Analysis | Global | 2026-2032

Global Autotransfusion Device Market Report to 2032

The global autotransfusion device market was valued at $321.2 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.7%, reaching $360.2 million by 2032.

This report covers the global market for autotransfusion devices, including autotransfusion disposable kits and autotransfusion machines used to collect, process, and reinfuse a patient's own blood.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by new and improved technologies, reduced transfusion-related complications, and a larger patient pool seeking alternatives to donor blood. However, allogeneic blood transfusions, stagnant capital equipment, and changing financing structures continue to limit stronger expansion.

Market Overview

The global autotransfusion device market includes systems and disposables used to recover and reinfuse a patient's own blood during or after surgery. These products are commonly used in procedures where blood loss is expected and where reducing exposure to donor blood is a clinical priority.

The market includes autotransfusion machines and autotransfusion disposables. Machines represent the capital equipment used to process collected blood, while disposables include the kits, reservoirs, filters, and other components used during each procedure.

Autotransfusion machines compete directly with allogeneic blood transfusions, which remain widely available and well established across most healthcare systems. Although autotransfusion offers safety advantages, the upfront cost of capital equipment can be a major barrier to adoption.

Budget limitations and competing capital priorities often lead hospitals to continue relying on donor blood instead of investing in dedicated autotransfusion systems. This is especially true in cost-constrained facilities and hospitals with limited expected use, where rising ASPs for capital equipment can make purchasing decisions more difficult.

Market Drivers

New and Improved Technologies

New and improved technologies are supporting growth in the autotransfusion device market. Over the past few years, three of the four companies offering autotransfusion devices have received U.S. Food and Drug Administration approval for new machines.

These newer systems include advances in washing and filtration technology. Improved processing can help provide a higher-quality blood product for reinfusion, supporting stronger clinical confidence in cell salvage.

As autotransfusion systems become more reliable and easier to use, hospitals may be more willing to evaluate them for selected procedures. Technology improvements also help manufacturers differentiate their products in a market where capital equipment decisions are often constrained by cost and utilization rates.

Reduced Complications

Autotransfusion reduces several risks associated with donor blood transfusion. By using the patient's own blood, the procedure eliminates the risk of complications such as transmission of bloodborne diseases.

Autotransfusion also avoids the risk of immune response associated with donor blood. Since the reinfused blood comes from the same patient, compatibility testing is not needed before infusion.

These clinical and safety advantages support autotransfusion use in procedures where blood loss is expected and where cell salvage is practical. Reduced complication risk remains an important factor for hospitals, physicians, and patients when evaluating alternatives to allogeneic transfusion.

Increased Patient Pool

Autotransfusion machines can help hospitals treat patients who refuse donor blood or who face added risks from donor blood exposure. This includes patients who avoid transfusions for religious reasons and patients who are immune deficient.

For these patient groups, autotransfusion may be one of the only acceptable or clinically preferred ways to support treatment when blood replacement is needed.

As hospitals seek to accommodate patient preferences and reduce the risks associated with donor blood, demand for autotransfusion can be supported in selected surgical settings. This expands the practical patient pool for autotransfusion devices, even in a market where broader adoption remains cost-sensitive.

Market Limiters

Alternatives

The main limiter of the autotransfusion device market is competition from allogeneic blood transfusion. Donor blood remains widely available and is already built into hospital workflows across most healthcare systems.

Because of cost pressures, many hospitals may be reluctant to purchase the capital equipment required for autotransfusion. This is especially true when donor blood is accessible, familiar, and supported by existing blood bank infrastructure.

The challenge becomes more significant if ASPs for capital equipment increase. When hospitals must choose between purchasing a new autotransfusion system and continuing to rely on allogeneic transfusion, budget constraints can limit adoption.

Stagnant Capital Equipment

Stagnant capital equipment is another important restraint in the autotransfusion market. Many facilities already have autotransfusion machines that are not used frequently.

This is partly the result of historical placement practices, where devices were given away for free or placed in facilities to encourage disposable use. Because clinical usage has remained low in some settings, these machines are often replaced slowly.

The cost of underused machines can be absorbed into the higher cost of disposables. Since it can be difficult to predict future need, hospitals may maintain more devices than are regularly used, which reduces the need for new capital purchases.

Changing Financing Structure

Financing has been the preferred option for many autotransfusion purchasing contracts in recent years. However, because autotransfusion device use can be volatile and limited, some facilities have not generated enough profitable use under this model.

As a result, the market has started to transition back toward upfront payments for capital equipment. This shift creates challenges for smaller facilities and hospitals with limited expected use.

The large upfront cost of autotransfusion machines can be difficult to manage in tighter hospital budgets. This changing financing structure may reduce adoption, slow replacement cycles, and limit market growth over the forecast period.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers autotransfusion devices used to collect, process, and reinfuse a patient's own blood, including autotransfusion machines and autotransfusion disposable kits.

Markets Covered and Segmentation

Autotransfusion Device Market

• Device type: Autotransfusion machines and autotransfusion disposables.

Autotransfusion machines are capital systems used to process blood collected during or after surgery. These machines support washing, filtration, and preparation of the patient's blood for reinfusion.

Autotransfusion disposables include single-use kits and related products used during each procedure. These may include reservoirs, filters, tubing, and other components required for blood collection and processing.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how capital equipment purchasing, disposable utilization, hospital budgets, clinical use patterns, and competition from donor blood are shaping the global autotransfusion device market.

Competitive Analysis

LivaNova was the leading competitor in the global autotransfusion market in 2025. The company has been active in the market for more than 30 years and launched its latest autotransfusion machine, XTRA.

LivaNova has continued to invest in the autotransfusion market, which supports expectations that the company will expand its market share over the coming years. Its long-standing presence, product experience, and continued technology investment reinforce its competitive position.

Haemonetics was the second-leading competitor in the autotransfusion market in 2025. The company currently offers the Cell Saver(R) Elite(R) and Cell Saver(R) Elite(R) + autotransfusion systems in the United States.

Haemonetics participates in a limited number of cardiac surgery device market segments. As competition between LivaNova and Medtronic strengthens, Haemonetics is expected to face pressure and lose share over the forecast period.

Medtronic was the third-leading competitor in the global autotransfusion market in 2025. The company offers the AutoLog IQ(TM), which is priced at a modest premium to its predecessor, autoLog(TM). Medtronic also offers disposables, including filters and reservoirs for autotransfusion procedures. Since Medtronic has left the ventricular assist device market, it is expected to expand its presence in the autotransfusion segment.

Technology and Practice Trends

Improved Washing and Filtration

Newer autotransfusion machines are improving washing and filtration performance. These advances help produce higher-quality blood products for reinfusion.

Improved processing is important for building clinical confidence and supporting use in procedures where blood salvage is needed.

Cell Salvage in Blood Management

Autotransfusion remains part of broader patient blood management strategies. Hospitals use these systems to reduce reliance on donor blood and support safer blood conservation practices.

This trend is especially relevant in surgeries where blood loss is predictable.

Disposable Kit Utilization

Disposable kits remain an important part of the market because they generate recurring revenue each time an autotransfusion procedure is performed.

Even when capital equipment replacement is slow, disposable use can support market value if procedure volumes remain stable.

Capital Equipment Replacement Cycles

Capital equipment replacement cycles are slow in many facilities. Underused machines, limited procedure volumes, and tighter budgets can delay new purchases.

Manufacturers must account for this slower replacement pattern when forecasting equipment demand.

Patient Preference and Religious Considerations

Autotransfusion can help hospitals accommodate patients who refuse donor blood for religious reasons. It can also support patients who want to avoid donor blood exposure for safety or personal reasons.

This creates a defined patient group where autotransfusion may be especially important.

Competition with Donor Blood

Allogeneic blood transfusion remains the main alternative to autotransfusion. Donor blood is established, widely available, and often easier for hospitals to use without purchasing new capital equipment.

This ongoing competition will continue to shape adoption and purchasing behavior.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global autotransfusion device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do autotransfusion machines and disposable kits play in surgical blood management?
• How do autotransfusion devices reduce exposure to donor blood?
• How are new washing and filtration technologies improving the quality of reinfused blood?
• Which patient groups are most likely to benefit from autotransfusion?
• How does competition from allogeneic blood transfusion affect market adoption?
• Why do stagnant capital equipment and slow replacement cycles limit growth?
• How are changing financing structures affecting hospital purchasing decisions?
• Which companies lead the global autotransfusion device market?

The Global Autotransfusion Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand blood management trends, and support commercial planning in the global autotransfusion device market.